Dudediligence.

Kymera Therapeutics, Inc

KYMRNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$3.7MSep ’24$7.4MDec ’24$22.1MMar ’25$11.5MJun ’25$2.8MSep ’25$2.9MDec ’25$34.4MMar ’26$65.0MJun ’26
Net income, by quarter
−$62.5MSep ’24−$70.8MDec ’24−$65.6MMar ’25−$76.6MJun ’25−$82.2MSep ’25$535.7MDec ’25−$69.2MMar ’26−$61.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$72.8M$46.8M$78.6M$47.1M$39.2M
Gross profitnone on file$0.00$0.00$0.00$0.00
Operating income−$100.5M−$161.3M−$165.5M−$261.6M−$349.4M
Net income−$100.2M−$154.8M−$147.0M−$223.9M$311.4M
Operating cash flow−$128.9M−$153.1M−$102.8M−$194.5M−$232.9M
Free cash flow−$130.5M−$155.9M−$137.3M−$207.3M−$234.3M
Cash$48.0M$68.4M$110.0M$120.3M$357.0M
Shares outstanding51.5M55.0M55.6M64.9M81.3M